



PRESS RELEASE

Movements within the LFB group

Les Ulis, 5 November 2015 – Denis Soubeyran is appointed General Director of LFB BIOMEDICAMENTS, a wholly-owned subsidiary of LFB SA, dedicated to plasma-derived medicinal products. Within the group, Léopold Berteau is heading up the new Global Bioproduction Division, managing LFB industrial activities in biotechnologies. The Group Executive Committee is welcoming four new executive directors.

Denis Soubeyran appointed General Director of LFB BIOMEDICAMENTS

Denis Soubeyran, 56 years (ENS 1984, ENA 1988, Harvard Business School 2004) is becoming General Director of LFB BIOMEDICAMENTS. This is a newly created position within the France subsidiary devoted to plasma-derived medicinal products, to reinforce LFB's commercial position in this field and to prepare for the future with, in particular, the new generation plant being built at Arras, which will enter into operation in 2020 and triple LFB's production capacity in plasma-derived medicinal products.

Christian Béchon, Chief Executive Officer of the LFB group, is remaining as Chairman of LFB BIOMEDICAMENTS.

Before joining LFB, Denis Soubeyran held several senior management roles with the Renault group, including financial director of Renault Samsung Motor and group Financial Operations Director. Beforehand, Denis Soubeyran had held various roles in the Court of Audit and was Principal Private Secretary to the French Minister of Education and Research in 1997.

Since September 2010, at LFB, Mr Soubeyran has been in charge of group strategy, planning, management audit, accounting and information systems, as part of his role as Financial Affairs and Strategy Director.

Léopold Bertéa is joining the LFB group to manage the newly created Global Bioproduction Division

Léopold Bertéa, 50 years, joined the LFB group in August 2015 to head up the Global Bioproduction Division, managing the group's industrial activities in biotechnologies: production of recombinant proteins, monoclonal antibodies and innovative therapeutic medicines. The creation of the Global Bioproduction Division must accelerate the maturation of LFB's industrial capacities in biotechnologies, two years from the planned launch of recombinant activated Factor VII and recombinant antithrombin in pre-eclampsia, in the United States. The LFB USA, LFB BIOMANUFACTURING and CELLforCURE subsidiaries bioproduction activity is supervised by this Global Bioproduction Division.

Mr Bertéa is also Vice-President of the LFB Biotechnologies subsidiary and member of the LFB group Executive Committee.

Mr Bertéa holds a PhD in "Chemical Engineering" from the ETH Zürich (Switzerland) and for more than twenty years has had roles in bioproduction management and biopharmaceutical development within pharmaceuticals companies such as Novartis and Sanofi group.

Newcomers to the LFB group (LFB SA) Executive Committee

Including Léopold Bertéa, the LFB Executive Committee is welcoming five new directors.

David Loison, 45 years, is entering the group Executive Committee as Director of Financial Affairs, replacing Mr Denis Soubeyran in this role. A graduate from IEP, Paris (1994), Mr Loison has been acting as Management Audit Director since 2008 for the LFB group. Beforehand, Mr Loison held various roles in finance, strategy and human resources within the Pechiney and Alcan groups, in particular occupying the positions of subsidiary financial director and business unit management audit director.

Yann Echelard, 51 years, is entering the group Executive Committee as Chief Executive Officer of the American subsidiary rEVO Biologics, specialised in the development and marketing of the recombinant antithrombin ATryn® in the United States. Mr Echelard holds a PhD in Microbiology and Immunology from the University of Montreal (1989) and has also carried out post-doctoral studies in North America. He joined Genzyme Transgenic Corporation in 1994. Since 2012 he has directed the company rEVO Biologics.

Joris Pezzini, 33 years, is entering the group Executive Committee as group Director of Strategy and Business Development. With a Master's in biotechnologies and certificate of Harvard Business School, Mr Joris Pezzini joined the LFB Financial Affairs Division in 2010 and since 2012 has directed the group's Strategic Planning Division.

Robert Verdeguer, 57 years, is entering the group Executive Committee as General Director of Quality and Pharmaceutical Affairs and Head Pharmacist of the subsidiary LFB BIOMEDICAMENTS, specialised in plasma-derived medicinal products. Mr Verdeguer, Doctor in Pharmacy, joined LFB in 2007 within the Pharmaceutical Affairs Division.

Aside from the new arrivals, the Group Executive Committee comprises: Marcia Bassit, General Director of the subsidiary LFB HEMODERIVADOS E BIOTECNOLOGIA LTDA, Christian Béchon, Chief Executive Officer of the LFB group, Patrick Bergeat, Deputy General Director of Operations and Industrial Director, Max Berger, Director of Legal Affairs,

Guillaume Bologna, General Director of Programmes, Sandrine Charrières, Director of Communication, Sami Chtourou, Deputy General Director of Innovation and Scientific Affairs, Jean-Noël Colin, Group Quality and Pharmaceutical Coordination Director, Jean-François Doré, Member of the Executive Board, EUROPLASMA Holding AT GmbH, Philippe Grédy, Global Marketing and Sales Director and Commercial Director, Denis Soubeyran, LFB BIOMEDICAMENTS General Director and Stéphane Valet, Director of Human Resources.

About the LFB Group *LFB is a biopharmaceutical group which develops, manufactures and markets medicinal products from living systems for the treatment of serious and often rare diseases in major therapeutic areas: haemostasis, immunology and intensive care. Number one in France and sixth in the world for plasma-derived medicinal products, the LFB group is also one of the leading European companies for the development and production of proteins and innovative treatment derived from biotechnologies. Relying on its sustained research effort, the LFB group is implementing a growth strategy to expand its activities to international markets. The LFB group currently markets products in 40 countries throughout the world and achieved a global turnover of 502 million Euros in 2014. It employs more than 2,000 people. <http://www.lfb.fr/>*

LFB S.A. contact

Sandrine Charrières – Corporate Communications Director
Tel: +33 (1) 69 82 72 80
email: charrieres@lfb.fr

Press contact

Havas Worldwide

Jeanne Bariller
Tel: +33 (6) 15 51 49 40
email: jeanne.bariller@havasww.com